Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Kisspeptin-10

KP-10, Metastin (45-54), Kisspeptin-10 (human), KiSS-1

Quick Stats
Studies 877
Trials 47
Score 2
2013 pubmed 98 citations

Endogenous mammalian RF-amide peptides, including PrRP, kisspeptin and 26RFa, modulate nociception and morphine analgesia via NPFF receptors.

Elhabazi. Khadija K; Humbert. Jean-Paul JP; Bertin. Isabelle I; Schmitt. Martine M; Bihel. Frédéric F; Bourguignon. Jean-Jacques JJ; Bucher. Bernard B; Becker. Jérôme A J JA; Sorg. Tania T; Meziane. Hamid H; Petit-Demoulière. Benoit B; Ilien. Brigitte B; Simonin. Frédéric F

Key Findings

  • Kisspeptin-10 binds strongly to NPFF1 and NPFF2 receptors, which are not very selective for specific RF‑amide peptides.
  • Activation of NPFF1/2 by kisspeptin‑10 (and other RF‑amide peptides) causes hyperalgesia and reduces morphine‑induced analgesia in mice.
  • The NPFF antagonist RF9 blocks the pain‑enhancing and morphine‑blocking effects, confirming NPFF receptors mediate these actions.

Practical Outcomes

  • If you’re considering kisspeptin‑10 for any health or performance purpose, be aware it may increase pain sensitivity and diminish opioid pain relief. Avoid using it together with opioid analgesics, and watch for any heightened pain response if you do take it.

Summary

The study shows that kisspeptin-10, like other RF‑amide peptides, can make mice more sensitive to pain and block the pain‑relief effects of morphine by acting on NPFF1/2 receptors. This effect is stopped by a drug that blocks those receptors, meaning the pain‑modulating action is real and not just a lab artifact.

Abstract

Mammalian RF-amide peptides are encoded by five different genes and act through five different G protein-coupled receptors. RF-amide-related peptides-1 and -3, neuropeptides AF and FF, Prolactin releasing peptides, Kisspeptins and RFa peptides are currently considered endogenous peptides for NPFF1, NPFF2, GPR10, GPR54 and GPR103 receptors, respectively. However, several studies suggest that the selectivity of these peptides for their receptors is low and indicate that expression patterns for receptors and their corresponding ligands only partially overlap. In this study, we took advantage of the cloning of the five human RF-amide receptors to systematically examine their affinity for and their activation by all human RF-amide peptides. Binding experiments, performed on membranes from CHO cells expressing GPR10, GPR54 and GPR103 receptors, confirmed their high affinity and remarkable selectivity for their cognate ligands. Conversely, NPFF1 and NPFF2 receptors displayed high affinity for all RF-amide peptides. Moreover, GTPγS and cAMP experiments showed that almost all RF-amide peptides efficiently activate NPFF1 and NPFF2 receptors. As NPFF is known to modulate morphine analgesia, we undertook a systematic analysis in mice of the hyperalgesic and anti morphine-induced analgesic effects of a representative set of endogenous RF-amide peptides. All of them induced hyperalgesia and/or prevented morphine analgesia following intracerebroventricular administration. Importantly, these effects were prevented by administration of RF9, a highly selective NPFF1/NPFF2 antagonist. Altogether, our results show that all endogenous RF-amide peptides display pain-modulating properties and point to NPFF receptors as essential players for these effects.

Study Information

Provider

pubmed

Year

2013

Date

2013-08-02T00:00:00.000Z

DOI

10.1016/j.neuropharm.2013.07.012

Citations

98

References

49